Psychology by BogdanovaThe Encyclopedia of Psychology for the Artificial Era

RESEARCH DOSSIER

Somatic Symptom, Illness Anxiety, and Functional Neurological Disorders

Abstract. This fundamental research monograph investigates somatic symptom disorder, illness anxiety disorder, and functional neurological disorder as overlapping but diagnostically distinct domains. It reconstructs the histories of somatization, hypochondriasis, conversion, and functional neurological diagnosis; compares DSM and ICD classification; analyzes bodily symptom perception, interoception, predictive processing, threat appraisal, health anxiety, learning, attention, motor agency, and clinical comorbidity; and assesses psychometric instruments, positive neurological signs, controlled interventions, and longitudinal outcomes. Original measurement studies, major randomized trials, systematic reviews, and official clinical guidance provide the evidence base. The synthesis distinguishes the validity of reported bodily experience from untested causal explanation, emphasizes positive diagnosis and medical differential assessment, and evaluates treatment findings according to primary endpoints and active comparators. It identifies unresolved problems in diagnostic boundaries, construct validity, mechanism discrimination, replication, health equity, and digital health systems.

Keywords: somatic symptom disorder; illness anxiety disorder; health anxiety; functional neurological disorder; FND; functional seizures; functional motor disorder; bodily distress; interoception; predictive processing; somatic symptoms; hypochondriasis; DSM-5-TR; ICD-11; PHQ-15; SSS-8; SSD-12; Health Anxiety Inventory; cognitive behavioral therapy; CODES; Physio4FMD; clinical psychology; neuropsychiatry; Artificial Era

Scientific Overview and Research Boundaries

Somatic symptom disorder, illness anxiety disorder, and functional neurological disorder constitute a consequential meeting point of clinical psychology, psychiatry, neurology, primary care, and behavioral medicine. The shared scientific question concerns the relationship among bodily experience, perceived threat, neurological performance, interpretation, behavior, and disability. Their clinical presentations may overlap, but their diagnostic objects differ. Somatic symptom disorder centers on distressing bodily symptoms accompanied by a sustained pattern of disproportionate symptom-related thoughts, affect, or behavior. Illness anxiety disorder centers on fear or conviction of serious illness when somatic symptoms are absent or relatively mild. Functional neurological disorder (FND) concerns involuntary neurological symptoms whose clinical presentation exhibits characteristic positive diagnostic features of altered functioning.

This monograph treats the three conditions as related research domains and preserves their distinctions. Physical symptoms are experiences with consequences in ordinary life; they may accompany demonstrable disease, occur in uncertain medical circumstances, or remain insufficiently explained after appropriate examination. None of these facts alone establishes a psychiatric diagnosis. Illness-related concern similarly ranges from adaptive vigilance to disabling preoccupation. Functional weakness, tremor, seizure-like episodes, sensory changes, speech disturbance, and other FND manifestations require neurological examination and phenotype-specific reasoning. The Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018) characterizes FND through positive signs and clinically meaningful dysfunction, providing an important starting point.

The inquiry organizes evidence at five levels: phenomenological description of symptoms and concern; formal diagnostic classification; cognitive, affective, behavioral, and neural theories; validated measurements and experimental designs; and comparative treatment outcomes. These levels cannot be collapsed into one universal mechanism. This is a critical narrative synthesis of published primary studies, selected systematic reviews, measurement validation research, clinical guidelines, and historical scholarship. No original participant data were collected, no meta-analysis was performed, and the cited effects are reported from the specified published sources.

The scientific task is to explain what contemporary evidence supports, how investigators reached those conclusions, where different constructs are confounded, and which research questions remain open. Closely related rehabilitation questions receive specialized treatment in the separately reserved dossier on Functional Neurological Disorder: Multidisciplinary Rehabilitation. The present dossier concentrates on diagnostic science, bodily prediction, health anxiety, symptom formation and interpretation, and the comparative empirical basis of care.

Research Questions and Evidence Architecture

Five central questions guide the analysis. First, how should bodily distress, illness threat, and altered neurological performance be defined and distinguished? Second, how did historical categories and current DSM and ICD classifications change the scientific objects under investigation? Third, what do attention, learning, interoception, expectation, agency, social context, and nervous-system processes contribute to explanatory models? Fourth, which measures and diagnostic observations establish credible, reproducible evidence? Fifth, what can be inferred from treatment trials and meta-analyses when primary outcomes, secondary outcomes, control conditions, and participant selection differ?

The sources include original psychometric investigations such as Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002), Salkovskis, P. M., Rimes, K. A., Warwick, H. M. C., & Clark, D. M. (2002), and Toussaint, A., Murray, A. M., Voigt, K., Herzog, A., Gierk, B., Kroenke, (2016); foundational explanatory research such as Van den Bergh, O., Witthöft, M., Petersen, S., & Brown, R. J. (2017); and controlled trials of health-anxiety or FND interventions. The World Health Organization. (2024) establish a current international diagnostic point of comparison.

Selection is purposive and question-led rather than exhaustive. Search discovery was directed toward international classifications, original scale studies, pivotal trials, primary clinical reviews, and integrative systematic syntheses. A published reference supports only the claims that its accessible abstract or full text actually substantiates. The review gives special weight to preregistered or clearly defined primary outcomes and distinguishes individual treatment response from superiority to an active comparator.

The evidence hierarchy is applied to the question actually asked. Controlled randomized trials offer stronger comparisons for treatment effects than retrospective case series; diagnostic accuracy requires reference standards and representative clinical samples; qualitative research can clarify patient experience and communication while supporting different forms of inference. Imaging correlates can motivate mechanistic hypotheses but do not automatically establish causation or a clinical biomarker.

Historical Development of Bodily Symptom Concepts

The categories now used in clinical research emerged through several partially competing histories. Nineteenth-century clinical investigators described complex syndromes combining bodily complaints, abnormal movement, sensory change, and distress. Pierre Briquet's 1859 treatise examined 430 patients and treated hysteria as a medical problem with multiple symptoms, a history reconstructed by Mai, F. M., & Merskey, H. (1981). Those observations were substantial for their time, but their case selection, social assumptions, and diagnostic framework cannot be read as modern validated epidemiology.

At the Salpêtrière, Jean-Martin Charcot investigated neurological presentations historically called hysteria, including altered movement and sensation. Pierre Janet and Sigmund Freud developed different psychological accounts, while Joseph Babinski advanced additional clinical interpretations. The Bogousslavsky, J. (2020) documents these shifting contributions. Hypnosis, suggestion, conversion, dissociation, and traumatic experience became important theoretical vocabularies. Historical influence alone does not establish any one mechanism as a universal explanation of today's heterogeneous presentations.

Twentieth-century classifications introduced somatization disorder, hypochondriasis, conversion disorder, and broader somatoform categories. Their emphasis on medically unexplained symptoms was clinically unstable because explanation depends on knowledge, examination, temporal evolution, and access to specialized assessment. The absence of an established organic explanation could be mistaken for evidence of a psychological cause. Researchers increasingly criticized such diagnostic reasoning for conflating epistemic uncertainty with a positive disorder criterion.

The twenty-first-century shift is therefore methodological as well as terminological. DSM-5 moved somatic symptom disorder toward clinically significant symptom-related psychological and behavioral features; FND diagnosis increasingly emphasized positive neurological phenomena. Dimsdale, J. E., Creed, F., Escobar, J., Sharpe, M., Wulsin, L., Barsky, (2013) describe the rationale for the DSM revision, whereas Mayou, R. (2014) illustrates a contemporaneous critique. Both perspectives matter: diagnostic revision addresses an inherited problem while generating new questions about the threshold for labeling disproportionate concern.

Classification in DSM and ICD

The DSM-5-TR uses the category somatic symptom disorder when one or more distressing somatic symptoms are associated with excessive thoughts, feelings, or behaviors relating to symptoms or health and the symptomatic state persists. A person may simultaneously have cancer, autoimmune disease, chronic pain, or another documented illness. The clinical judgment concerns the whole symptom-related pattern and its context. The diagnostic architecture was introduced by the Dimsdale, J. E., Creed, F., Escobar, J., Sharpe, M., Wulsin, L., Barsky, (2013). The disorder is not synonymous with unexplained symptoms, a high symptom count, or a positive screening score.

Illness anxiety disorder describes sustained preoccupation with having or acquiring serious illness, usually with absent or mild somatic complaints. Health-related behaviors may be excessive, such as repeated checking and reassurance seeking, or avoidant, such as reluctance to obtain medical attention. Classification depends on duration, distress, impairment, contextual proportionality, and exclusion of better-fitting explanations. DSM categories organize clinical communication; their labels do not by themselves disclose neurobiological etiology.

Functional neurological symptom disorder, also called conversion disorder in DSM nomenclature, has one or more symptoms affecting voluntary motor or sensory function, with evidence of incompatibility between the symptom and recognized neurological or medical conditions. Current neurological practice relies on positive clinical characteristics and appropriate differential assessment. The Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018) explains why the diagnosis does not require a demonstrable psychological precipitant or the presumption of feigning.

ICD-11 uses an organizational scheme that differs from DSM. Its clinical classification recognizes bodily distress disorder, hypochondriasis in the obsessive-compulsive and related disorders grouping, and dissociative neurological symptom disorder in the dissociative disorders grouping. Terminology and boundaries should therefore be mapped conceptually instead of treated as one-to-one translation. The authoritative international framework is the World Health Organization. (2024); diagnostic reporting should identify its applicable national edition and clinical purpose.

Construct Boundaries and Diagnostic Overlap

The common feature across the present field is a problem of bodily interpretation or functioning, yet disorder identity depends on what constitutes the clinical target. In somatic symptom disorder, consequential symptoms and the pattern of concern or behavioral engagement jointly matter. In illness anxiety disorder, concern about a serious diagnosis is prominent even when current bodily symptoms are limited. In FND, positive features of altered neurological action or sensation define the clinical presentation. Co-occurrence is plausible because a person with functional weakness can also develop substantial health anxiety, and a person with inflammatory disease can develop somatic symptom disorder.

A conceptual error arises when symptom severity, perceived seriousness, and diagnostic category are treated as identical variables. Persistent pain does not quantify disease-specific catastrophic appraisal; frequent checking does not prove neurological dysfunction; functional tremor entrainment is not evidence of somatic symptom disorder. Measures should be chosen according to target construct rather than administrative convenience. The instrument comparisons by Toussaint, A., Hüsing, P., Kohlmann, S., & Löwe, B. (2020) demonstrate that somatic burden and psychological diagnostic features require complementary measurement.

Diagnosis must also distinguish clinical distress from ordinary concern during genuine uncertainty. A new symptom, a family history of severe disease, or a previous medical diagnostic error may reasonably intensify monitoring. Social background, health literacy, language, disability access, treatment experiences, and risk exposure influence what appears disproportionate. Standardized criteria create reproducibility goals, while the final assessment demands attention to actual medical context.

The three subjects share theoretical constructs—selective attention, learning, predictive inference, avoidance, and perceived agency—without requiring that these constructs operate identically. An integrated clinical formulation can recognize convergent processes and preserve disorder-specific evidence. Research benefits from modeling overlap as a measured property rather than quietly merging diagnoses in one convenience sample.

Bodily Experience and Interoceptive Inference

Interoception denotes the sensing, integration, and interpretation of signals concerning the body's internal state. Bodily experience arises through peripheral signals, central processing, learned expectations, contextual information, and response selection. Laboratory work can study respiratory resistance, cardiac perception, pain, gastrointestinal discomfort, and other modalities, but performance on one interoceptive task does not establish a generalized capacity that applies equally to all bodily experiences.

Van den Bergh, O., Witthöft, M., Petersen, S., & Brown, R. J. (2017) describe an inferential account in which observed bodily sensation and objectively measured physiology vary in correspondence. Their framework uses predictive coding to explain how expectations and sensory evidence jointly shape experience. Its theoretical attraction lies in integrating otherwise disparate symptom phenomena while generating experimentally testable propositions concerning uncertainty, learned associations, and attention.

Prediction-based theories remain models rather than clinical diagnostic tests. A predictive-processing description may help explain why a symptom fluctuates with expectation or context, but a broad framework is compatible with many outcomes and must yield precise falsifiable predictions. Studies need well-specified manipulations, physiological measurements, independent replication, and control for demand characteristics. Otherwise explanatory vocabulary risks simply re-describing an observed symptom.

The research implication is to measure bodily signal, expected threat, attention, and subjective report together, ideally repeatedly within individuals. Their divergences are themselves data. They cannot establish that the symptom is intentionally produced or that physical illness has been excluded. The same person may experience a documented medical problem and an expectation-driven amplification of certain aspects of bodily sensation.

Threat Appraisal and Health Anxiety

Health anxiety is an appraisal process in which sensations, diagnostic possibilities, or health information are interpreted as threats to bodily integrity. It can be understood dimensionally across ordinary concern, persistent high anxiety, and clinically significant illness preoccupation. The Salkovskis, P. M., Rimes, K. A., Warwick, H. M. C., & Clark, D. M. (2002) measures health-related worry and associated beliefs without assuming that all elevated scores indicate a categorical diagnosis.

Cognitive-behavioral accounts propose that ambiguous sensations become cues for catastrophic interpretation, leading to vigilance, checking, reassurance seeking, repeated testing, internet searches, and short-term relief. Such safety behaviors can leave the original belief insufficiently tested and contribute to recurring anxiety. Avoidance of hospitals or health information can sustain uncertainty through a different pathway. These are hypotheses about maintaining processes that require attention to the person's medical reality and the intended function of each behavior.

Some research illustrates the clinical tractability of this formulation. In the randomized trial by Barsky, A. J., & Ahern, D. K. (2004), a structured cognitive-behavioral approach was compared with usual medical care for participants diagnosed under the historical hypochondriasis framework. Hedman, E., Andersson, G., Andersson, E., Ljótsson, B., Rück, C., Asmund (2011) tested an internet-delivered approach for severe health anxiety. These results support investigation of fear, appraisal, and behavior as modifiable targets, while historical case definitions limit automatic generalization to all people carrying contemporary illness anxiety disorder diagnoses.

A scientifically adequate account also considers genuine risk. Reassurance may be clinically necessary when new findings arise, and repeated medical assessment may have a sound indication. The research problem is to distinguish behavior guided by an evolving clinical situation from behavior maintained predominantly by an anxiety loop. That distinction is practical, ethical, and empirically measurable.

Attention, Vigilance, and Symptom Monitoring

Attention shapes which bodily sensations enter awareness and how strongly they are weighted. Selective vigilance can make minor changes more salient, while threat context encourages repeated interpretation. The connection is dynamic: bodily discomfort attracts attention, attention can intensify discomfort, and intensified discomfort can elicit further protective behavior. Such reciprocal patterns are consistent with the Van den Bergh, O., Witthöft, M., Petersen, S., & Brown, R. J. (2017).

Experimental attention research must control for baseline symptom intensity, expectancy, general arousal, task instructions, and response bias. If an experiment asks people to monitor bodily sensations, an increased number of symptom reports may reflect additional detection, greater reporting propensity, or changes in experienced intensity. A single self-report outcome cannot identify which process changed. Within-subject designs and combined physiological measurements strengthen inference.

In health anxiety, attention can preferentially sample evidence consistent with feared illness. In FND, attention to consciously controlled movement may interfere with more automatic action patterns for certain phenotypes; this is one reason investigators distinguish voluntary initiation from automatic performance. Yet such accounts remain phenotype-sensitive, and clinical findings cannot be reduced to universal attentional causation.

The strongest synthesis preserves a bidirectional model: physical signals shape cognition and cognition modifies perception and behavior. The empirical task is to estimate each pathway under controlled conditions, rather than to assign priority by disciplinary preference.

Learning, Reassurance, Avoidance, and Maintenance

Repeated illness-related checking, searching, and consultation may function as attempts to reduce uncertainty. When temporary relief follows checking, the behavior can be negatively reinforced; when information contains additional alarming possibilities, worry can increase further. Avoidance can also protect threatening expectations from corrective experience. These mechanisms are familiar to learning theory but require disorder-specific validation in longitudinal and experimental research.

The distinction between an intervention target and a causal origin is essential. A behavior can maintain contemporary distress even when the initial episode began with infection, injury, medication effects, trauma, or another medical event. Successful treatment of a maintenance process does not retroactively prove a psychological origin for the first symptom. The intervention research reviewed by Van Dessel, N., den Boeft, M., van der Wouden, J. C., Kleinstäuber, M., (2014) is compatible with changing symptom-related behaviors as one pathway to improvement but cannot establish a common developmental cause for all cases.

Illness anxiety treatments often include structured reduction of checking or reassurance rituals, behavioral experiments, and exposure to uncertainty. FND interventions may direct attention to automatic movement patterns or reduce maladaptive responses to functional seizures. These interventions can intersect conceptually without becoming interchangeable. Behavioral procedures ought to be evaluated against disability and adverse-outcome measures, not simply a reduction in clinician-observed reassurance seeking.

Longitudinal models should include feedback from social environment and healthcare systems. Inconsistent professional messages, diagnostic delays, inaccessible specialty care, and fragmented follow-up may reinforce uncertainty independently of a patient's disposition. Causality can run through clinical institutions as well as individual cognition.

Agency, Automaticity, and Functional Neurological Symptoms

The sense of agency is the experience of initiating or controlling action. Functional movement symptoms provide a clinical window into relationships among voluntary intention, automatic movement, attention, and self-monitoring. A functional weakness examination may show a discrepancy between attempted voluntary force and automatic activation in another maneuver. A functional tremor may change with rhythm matching or distraction. These are positive clinical phenomena whose interpretation depends on neurological expertise and the total examination.

Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018) synthesize modern diagnostic reasoning and explain why positive signs have clinical value. Their presence indicates characteristics compatible with a functional presentation; it does not demonstrate deliberate performance. Positive signs are not substitutes for assessing possible neurological comorbidity. An individual can simultaneously have FND and epilepsy, migraine, multiple sclerosis, or another disease, and symptoms may evolve.

Mechanistic theories include altered attention, prior expectations, emotional salience, motor selection, and mismatches between intended action and experienced control. These constructs organize laboratory questions about task performance, symptom fluctuation, agency judgments, and neural activity. A clinical sign establishes a phenomenon more directly than it establishes a complete etiological theory.

Research quality depends on transparent phenomenological definitions and reliable examiner training. Interrater variability, referral selection, and discrepancies between clinical signs and experimental tasks can limit generalization. Studies that describe agency differences should disclose whether the measure captures explicit belief, implicit temporal judgment, movement accuracy, or subjective effort.

Functional Seizures and Diagnostic Evidence

Functional seizures, also described in historical literature as psychogenic nonepileptic or dissociative seizures, are episodes resembling epileptic seizures that have a different clinical basis. Their expression may involve altered awareness, movement, or responsiveness. Individual episodes require careful characterization: one descriptive label cannot establish whether other episode types are epileptic, syncopal, sleep-related, or otherwise medically explained.

The Tolchin, B., Goldstein, L. H., Reuber, M., Stone, J., Perez, D. L., LaFr (2026) emphasizes detailed history and witness accounts, including video when available, with video-EEG for typical episodes where feasible. The evidentiary significance of an EEG recording depends on whether a representative habitual event was captured and how the clinical event was interpreted. The absence of epileptiform findings in an unrelated short EEG is not automatically diagnostic of functional seizures.

The CODES randomized trial reported by Goldstein and colleagues (2020)30128-0) compared standardized medical care with and without tailored cognitive-behavioral therapy. Its primary comparison at 12 months—monthly functional-seizure frequency—was not statistically significant, although several secondary measures favored additional therapy. Both facts must be reported together, preserving the prespecified analytic hierarchy and the difference between symptom frequency and psychosocial function.

The clinical research program must also address mixed epileptic and functional seizures, detection accuracy, psychiatric comorbidity, disability, treatment adherence, and the burden of diagnostic uncertainty. The goal of classification is appropriate management and meaningful outcome measurement, rather than a binary assertion about whether an episode is real.

Pain, Fatigue, Dizziness, and Multisymptom Presentations

Persistent bodily complaints frequently span several systems. Pain, fatigue, dizziness, gastrointestinal discomfort, cardiopulmonary sensations, and cognitive complaints can occur in medically diagnosed diseases, functional syndromes, and clinical distress presentations. The scientific challenge is to avoid using a symptom list as an etiological diagnosis. A multidomain symptom inventory describes burden; it does not specify whether an inflammatory, neurological, endocrine, cardiovascular, vestibular, medication-related, or psychiatric process explains the complaints.

The Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002) established one practical way to quantify somatic symptom severity. The later Gierk, B., Kohlmann, S., Kroenke, K., Spangenberg, L., Zenger, M., Brähl (2014) examined a shorter symptom-burden measure in a German population survey. These instruments are valuable for severity, longitudinal change, and research comparison, but they omit the entire clinical examination and cannot establish a unique psychiatric condition in isolation.

Symptom clustering may reflect shared biology, correlated exposures, general distress, response processes, or recruitment through a specialty service. Network-style statistical models are sensitive to how symptoms are measured and which variables are omitted. An association between fatigue and health anxiety does not establish the direction of influence; the burden of ongoing illness can itself generate anxiety.

Integrated research therefore distinguishes multimorbidity, symptom intensity, emotional distress, work or social impairment, and healthcare encounters. These may change at different rates during treatment. A person whose symptom score changes little can nonetheless regain participation, and a person reporting lower symptom burden can retain major disability. Outcomes should be interpreted as complementary, not interchangeable.

Psychological Stress, Trauma, and Causal Heterogeneity

Stressful experience can influence attention, physiology, learning, social support, sleep, and symptom interpretation. Some individuals describe a significant life event before the onset of bodily or functional symptoms, whereas others report onset following illness or injury or identify no salient psychological precipitant. Diagnostic science must preserve this heterogeneity. A universal psychogenic origin would make a clinical classification depend on an unverified historical explanation.

Modern FND guidance no longer makes an identifiable psychological stressor a prerequisite for diagnosis. This development is described in Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018). At the same time, trauma exposure, adverse childhood experience, and current stress remain legitimate research variables with potential significance for some participants. Associations must be evaluated against confounding, retrospective recall, coexisting conditions, and the base rate of stressful events in comparison populations.

Case-control studies of life events require careful time windows, independent assessment, and attention to selection bias. Simply asking patients about adversity after receiving a diagnosis may inflate explanatory confidence through hindsight. Prospective studies and pre-registered mediation hypotheses can better separate predictors, triggers, maintaining processes, and correlates.

Ethical implications follow directly from empirical humility. Patients should not be required to endorse a trauma narrative for their symptoms to be taken seriously, and an identifiable stressor does not negate medical investigation. Mechanism-based interventions can remain useful even when etiology is uncertain or multiple contributing pathways operate simultaneously.

Neurobiology, Neuroimaging, and Causal Explanation

Functional neurological symptoms involve the nervous system because movement, sensation, awareness, and agency depend on neural processes. Research has explored functional networks related to motor control, salience, emotional regulation, attention, and self-representation. Imaging differences between clinical groups and controls can identify potentially important correlates, but they do not by themselves discriminate among primary causal changes, symptom consequences, medication or comorbidity effects, and task-related confounds.

The Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018) identifies plausible biological and psychological research directions. The more recent Ertenu, D. D., Papolu, A., Quezada, J., Jadhav, S., Dean, S., & Salpekar (2026) illustrates continued interest in neural organization across FND presentations. Such cross-phenotype work must avoid assuming that seizures, weakness, abnormal movement, and sensory symptoms share one decisive biomarker.

Small clinical imaging samples, differences in task performance, variable diagnostic inclusion criteria, group-level inference, and flexible analytical choices are important threats to reproducibility. Studies should report motion correction, medication status, psychiatric and neurological comorbidity, diagnostic certainty, and multiple-comparison procedures. Independent prospective validation is necessary before neuroimaging can be assigned a routine diagnostic role.

A functional diagnosis means that characteristic neurological functioning has been observed. It offers no scientific justification for describing a person as having a structurally flawless nervous system. Current research emphasizes mechanism, phenotype, and clinically meaningful outcomes; imaging is one source of evidence within that program.

Medical Differential Diagnosis and Longitudinal Safety

Assessment begins with a competent account of the symptom, its temporal course, associated signs, exposures, medical history, examination findings, and changes in functioning. A new focal deficit, altered consciousness, rapidly progressive neurological symptom, cardiovascular complaint, or other concerning presentation can warrant urgent medical evaluation according to ordinary clinical practice. Evidence-based psychiatric diagnosis does not authorize ignoring evolving bodily findings.

For FND, positive examination signs and relevant clinical history support diagnosis, while investigations are selected according to plausible alternatives and comorbidities. The NHS Scotland. (n.d.) explicitly addresses positive diagnosis and the need to consider coexisting disease. For persistent multisystem symptoms, assessment can involve repeated review when the trajectory changes without turning every symptom fluctuation into limitless testing.

Two diagnostic hazards are symmetrical in consequence: repeated testing without coherent indication can expose patients to burden and incidental findings, while premature diagnostic closure can delay recognition of medical disease. Coordinated care is intended to make both errors less likely. A stable point of clinical contact, planned reassessment, and explicit thresholds for new investigation can improve interpretability of care.

Research on diagnostic accuracy should follow patients longitudinally and document corrected diagnoses, additional diagnoses, missed conditions, and healthcare consequences. Cross-sectional validation alone cannot estimate delayed recognition or the safety of a label over time. The relevant unit is a diagnostic process with follow-up, rather than a single encounter.

PHQ-15 and SSS-8 Symptom Burden Measurement

The Patient Health Questionnaire-15 is a patient-reported inventory intended to quantify common somatic symptoms. In Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002), validation examined its relation to functional status, healthcare use, and other indicators. Its scientific utility is substantial because symptom count and severity can be tracked consistently across time and samples. Its interpretive boundary is equally important: a high score does not distinguish somatic symptom disorder from complex medical illness, and its items do not measure the whole psychological component of that disorder.

The Somatic Symptom Scale-8 reduces respondent burden while retaining coverage of major bodily symptom domains. In Gierk, B., Kohlmann, S., Kroenke, K., Spangenberg, L., Zenger, M., Brähl (2014), a nationally representative German sample of 2,510 people supported reliability and provided reference distributions. The reported internal consistency coefficient was approximately .81. The measure was associated with depression, anxiety, general health, and use of healthcare, illustrating construct convergence while also demonstrating that the domains overlap.

Comparison studies such as Gierk, B., Kohlmann, S., Toussaint, A., Wahl, I., Brünahl, C. A., Murray (2015) evaluate performance and interchangeability. Instrument choice must consider age, language, clinical setting, item meaning, missing data, and the purpose of measurement. Equivalence of correlations in one sample does not guarantee equivalent change sensitivity or invariance in a different cultural population.

A rigorous dataset reports separate scores for bodily symptom burden, excessive symptom-related cognitions or behaviors, clinically significant distress, and medical diagnoses. Separating these variables avoids building the diagnostic conclusion into the measurement instrument. No single brief questionnaire replaces a structured clinical assessment.

SSD-12 and the Psychological Features of Somatic Symptom Disorder

The Somatic Symptom Disorder–B Criteria Scale (SSD-12) was designed to measure the cognitive, affective, and behavioral features associated with DSM-5 somatic symptom disorder. Its development by Toussaint, A., Murray, A. M., Voigt, K., Herzog, A., Gierk, B., Kroenke, (2016) addressed a measurement problem generated by the diagnostic revision: somatic symptom burden and symptom-related psychological reactions represent related but distinguishable constructs. The reported clinic validation evaluated twelve items across three groups of psychological criteria.

In a later diagnostic accuracy study, Toussaint, A., Hüsing, P., Kohlmann, S., & Löwe, B. (2020) compared the PHQ-15, SSS-8, and SSD-12 against interview-based criteria in 372 psychosomatic outpatients. The area under the curve was about .70 for PHQ-15, .71 for SSS-8, and .74 for SSD-12, while combining the SSS-8 with SSD-12 produced an AUC near .79. These results indicate some improvement from combining symptom and psychological dimensions, while the remaining classification errors matter for clinical use.

The term criterion validity requires care because diagnostic interviews themselves operationalize the contested clinical threshold. If the reference standard depends on judgments about disproportionate worry, an instrument can approximate that decision without validating the underlying construct in every population. External longitudinal outcomes and independent clinician assessment remain valuable complementary standards.

The SSD-12 should therefore be treated as one information source. Interpretation must account for symptom severity, demonstrable disease, understandable fear in the face of actual risk, socioeconomic constraints, and health-system interactions. Psychometrics enables more transparent research but does not remove the need for contextual clinical judgment.

Health Anxiety Inventory and Behavioral Assessment

The Salkovskis, P. M., Rimes, K. A., Warwick, H. M. C., & Clark, D. M. (2002) was developed to assess health anxiety along a continuum and to distinguish anxiety-related appraisals from mere physical illness. Its items can inform longitudinal studies, clinical trials, and analysis of treatment mechanisms. Interpretation depends on the specific version used, scoring conventions, language validation, and appropriate reference distributions.

Self-report should be supplemented by assessment of checking, symptom monitoring, avoidance, reassurance seeking, clinical utilization, and functional interference. Structured diaries may capture when fear intensifies, which bodily cues precede it, and what follows help-seeking or avoidance. Repeated measurement permits within-person tests that are obscured when a patient is represented by a single intake score.

Researchers must recognize reactivity. A diary that asks a participant to inspect bodily states repeatedly can itself increase vigilance. Designs can test whether sparse measurement, event-contingent sampling, or neutral prompts change reports. Wearable monitoring similarly introduces information, alerts, and new opportunities for reassurance seeking; observed associations may reflect both underlying health status and the monitoring intervention.

Measurement across chronic illness populations raises additional validity questions. People with real, unstable medical disease may check for medically indicated warning signs. Labeling any checking behavior as excessive would sacrifice clinical specificity. Behavior becomes a research construct through its context, function, proportionality, and consequences.

Diagnostic Reliability, Prevalence, and Sampling

Reliable diagnosis requires agreement about criteria, training, and their application in real clinical settings. Prevalence estimates cannot be interpreted without information about the sampled population, recruitment site, diagnostic interview, symptom threshold, and exclusion rules. Estimates from medically referred clinics, psychiatric services, general population surveys, and neurological specialty centers may differ substantially because these settings select different people.

The conceptual revision described by Dimsdale, J. E., Creed, F., Escobar, J., Sharpe, M., Wulsin, L., Barsky, (2013) changes what an epidemiological study actually counts. Historical medically unexplained symptom categories and contemporary somatic symptom disorder samples have partially overlapping but distinct inclusion criteria. Combining them into one time trend can create a classification artifact. Likewise, hypochondriasis trials may encompass participants now labeled differently under DSM and ICD.

FND epidemiology also depends on phenotype. A study of functional seizures does not estimate prevalence of functional motor symptoms, and a movement-disorders clinic excludes many patients whose presentations occur elsewhere. Referral pathways and differential access influence apparent demographic distribution. Clinical case ascertainment needs diagnostic methods, not a generic checkbox for neurological complaints.

Research should report both point estimates and uncertainty, as well as denominators and ascertainment strategy. Where population-level evidence is weak, the academically sound conclusion is that prevalence remains incompletely established for the particular diagnostic category and setting. The existence of burden is well documented; precise numerical comparisons demand additional study-specific evidence.

Cognitive Behavioral Therapy for Health Anxiety

Cognitive-behavioral therapy for health anxiety typically organizes attention, interpretation of bodily evidence, safety behaviors, and avoidance into a testable formulation. In treatment studies, techniques may include exposure to uncertainty, behavioral experiments, reevaluation of illness probability, reduction of excessive checking, and collaborative work on functional priorities. The mechanism claimed for each technique must be distinguished from observed treatment efficacy.

Barsky, A. J., & Ahern, D. K. (2004) conducted a randomized trial comparing CBT with usual care among patients with hypochondriasis. Tyrer and colleagues (2014)61905-4) tested CBT for health anxiety among medical patients in the CHAMP trial. Hedman, E., Andersson, G., Andersson, E., Ljótsson, B., Rück, C., Asmund (2011) extended research to internet-based CBT in severe health anxiety. These investigations address distinct delivery settings and enrollment definitions while collectively strengthening the case for studying health anxiety as a modifiable clinical target.

Long-term follow-up is essential because illness-related concern can recur when new medical information appears. Tyrer, P., Wang, D., Crawford, M., Dupont, S., Cooper, S., Nourmand, S., (2021) reported longer-term findings from the CHAMP research program. Follow-up data can evaluate persistence of benefit but are vulnerable to attrition and evolving treatment exposure, which should be disclosed.

Cognitive-behavioral therapy is a structured intervention family rather than one uniform dose. Treatment components, therapist competence, comparator intensity, adherence, clinical comorbidity, and baseline anxiety determine how results should be generalized. An average group effect should never be presented as a prediction of individual benefit.

Digital Interventions and Health Information Environments

Internet-delivered psychological interventions extend access to people for whom specialist appointments are limited by geography, scheduling, stigma, or service capacity. Their scientific evaluation requires separation of the treatment content from the delivery technology. A structured online intervention incorporating evidence-based exposure and cognitive-behavioral tasks is different from unguided search-engine use or generalized self-help material.

In a randomized trial, Hedman, E., Axelsson, E., Andersson, E., Lekander, M., & Ljótsson, B. (2016) compared internet-delivered exposure-based CBT and bibliotherapy approaches for people meeting somatic symptom disorder or illness anxiety disorder criteria. A Shi, C., Zhang, T., Du, X., Lu, S., & Witthöft, M. (2024) included nine randomized trials and 1,079 participants, reporting a pooled between-group health-anxiety effect of Hedges' g around .70. Effects were larger against passive comparators than against active conditions, an important qualification for comparative efficacy.

Digital health search presents a parallel behavioral research problem: information may improve appropriate care, but repetitive threat-focused searching can sustain uncertainty. Research on online checking should distinguish ordinary information seeking, access barriers, safety behavior, commercial design incentives, and actual medical risk. Causal attribution to a digital platform requires experimental or longitudinal evidence; a correlation between searching and anxiety is insufficient.

In the Artificial Era, conversational assistants and algorithmic triage tools introduce additional experimental variables: probability framing, confidence language, source visibility, error correction, accessibility, and the capacity to reinforce or interrupt checking cycles. Their role should be studied through prospective safety and effectiveness trials, with independent clinical ground truth. The existence of an intelligent interface does not make its reassurance medically reliable.

Psychological Interventions for Persistent Somatic Symptoms

Treatment research for persistent somatic symptoms encompasses heterogeneous diagnostic labels and clinical settings. It includes structured cognitive-behavioral interventions, behavioral methods, psychodynamic approaches, mindfulness-related methods, and models integrated with medical care. Combining those designs into a pooled effect requires attention to intervention similarity, the target syndrome, outcome definition, follow-up, and trial quality.

The Van Dessel, N., den Boeft, M., van der Wouden, J. C., Kleinstäuber, M., (2014) included 21 randomized studies enrolling 2,658 participants under historical somatoform or medically unexplained symptom definitions. For psychological treatment versus usual care or waiting list, its pooled end-of-treatment symptom-severity effect was small to moderate, standardized mean difference about −0.34 with 95% confidence interval −0.53 to −0.16 among the comparable studies. The reviewers graded much of this evidence low quality and identified high risk of bias relating to blinding and attrition.

A striking methodological detail is the comparator. The same synthesis found no clear overall superiority when psychological interventions were compared with enhanced or structured care rather than ordinary care or waiting list. This does not negate observed benefit; it limits claims that a specific psychotherapy component accounts for an effect beyond well-organized, responsive clinical contact. Treatment acceptability and missing adverse-event reporting also require attention.

The term medically unexplained symptoms in older trials cannot be silently converted into a contemporary diagnosis of somatic symptom disorder. Research populations are constructed through their own entry criteria. The legitimate synthesis is that structured psychological care can improve some outcomes in certain groups, while effect magnitude, specificity, durability, and accessibility remain context-dependent.

Functional Motor Disorder Intervention Evidence

Specialist physiotherapy for functional motor symptoms is based on principles such as explaining positive clinical signs, retraining movement through automatic or externally focused tasks, and building participation. Its mechanism-oriented rationale should be distinguished from claims of proven superiority over alternative neurological rehabilitation. The focus of this dossier is the evidentiary evaluation, with detailed rehabilitative practice reserved for the dedicated FND rehabilitation research object.

The Physio4FMD trial reported by Nielsen and colleagues (2024)00135-2) randomized adults with clinically definite functional motor disorder to specialist physiotherapy or usual neurological physiotherapy care at centers in England and Scotland. The primary 12-month SF-36 physical-functioning comparison in the analyzed population showed an adjusted mean difference of 3.5 points, 95% confidence interval −2.3 to 9.3, with p = .23. The primary outcome therefore did not establish superior physical functioning for specialist physiotherapy.

Several secondary outcomes, including participant-rated motor improvement, favored the specialist intervention. The Nielsen, G., Marston, L., Hunter, R. M., Carson, A., Goldstein, L. H., H (2025) elaborated outcomes, safety, implementation and economic modeling. Those findings are informative but must not be substituted for the designated primary endpoint. The study's COVID-era disruption also complicated delivery and analysis, and patient-reported outcomes were susceptible to nonblinded expectancy effects.

Future motor trials should measure objective and patient-valued functioning, analyze missing data transparently, compare active treatments with credible intensity, and test whether phenotype, symptom duration, access, and therapeutic competence modify benefit. Positive treatment narratives cannot replace comparative causal evidence.

Functional Seizure Psychotherapy Trials and Guidelines

The CODES program is important because it directly tests a widely discussed psychological treatment in a large pragmatic design. In Goldstein and colleagues (2020)30128-0), participants received standardized medical care alone or combined with functional seizure–specific CBT. The 12-month primary outcome of seizure frequency did not show statistically significant superiority for the CBT arm. In the extended trial report, the estimated incidence rate ratio was 0.78, with a 95% confidence interval of 0.56 to 1.09 and p = .144; multiple secondary outcomes, including psychosocial functioning and perceived improvement, favored added treatment.

This pattern illustrates why endpoint hierarchy matters. A claim that CBT eliminates functional seizures would exceed the findings, while a claim that the treatment has no relevant effect would overlook improvements in separately measured outcomes. Secondary endpoints generate a differentiated clinical picture, particularly when participants value social participation and seizure-related distress in addition to frequency.

The Tolchin, B., Goldstein, L. H., Reuber, M., Stone, J., Perez, D. L., LaFr (2026) reviewed evidence available through February 2025 and reported that psychological interventions are possibly effective across several functional-seizure outcomes, with overall certainty constrained by study classification and heterogeneity. Guideline recommendations are a synthesis of evidence and judgment, not an independent randomized experiment.

FND treatment comparisons should identify seizure subtype, diagnostic confidence, coexistence of epilepsy, psychotherapy components, medication exposure, and quality of standardized medical care. Risks of unnecessary antiseizure medication for isolated functional seizures must be distinguished from appropriate treatment of documented epilepsy. Recommendations for individual patients remain the responsibility of qualified treating clinicians.

Shared Care and the Therapeutic Relationship

Patients in these research domains often encounter multiple specialties. Poor coordination can turn diagnostic uncertainty into repeated conflicting messages, while failure to explain the rationale for a positive diagnosis can undermine trust. Evidence-based service design therefore involves communication and continuity as measurable care processes. The Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018) identifies the consequences of delayed or poorly explained FND diagnoses.

A coherent consultation can make clear which observations support a diagnosis, which competing medical possibilities were evaluated, what changes would prompt reassessment, and what outcomes matter to the person. Research can assess understanding, alliance, treatment engagement, symptom burden, work or educational participation, and unplanned service use after different communication approaches.

Patients with substantial symptom distress are vulnerable to stigma if clinicians interpret psychological evaluation as a judgment about credibility. The National Health Service. (n.d.) explicitly recognizes that symptoms are experienced as real and may cause serious impairment. Clinical language should respect that empirical reality while preserving diagnostic specificity.

Care coordination itself can be an active ingredient in trials. A structured comparator may offer more predictable attention, explanation, and follow-up than usual care; this may reduce the incremental benefit attributed to a specific psychotherapy. Comparative design must measure what each group actually receives.

Comorbidity and Differential Psychological Processes

Anxiety, depressive symptoms, trauma-related difficulties, insomnia, chronic pain, and other conditions may coexist with somatic symptom disorder, illness anxiety disorder, or FND. Co-occurrence can shape disability, healthcare utilization, and treatment experience, but it does not prove that any coexisting psychiatric condition caused the bodily or neurological presentation. The absence of a mental disorder also does not invalidate a positively supported FND diagnosis.

Research should evaluate both shared and distinct mechanisms. General anxiety may increase attention to threat; low mood can reduce activity and social participation; sleep disruption can affect pain and fatigue; medication effects can alter perception or coordination. These are plausible bidirectional pathways whose effects differ across people. Cross-sectional correlations cannot determine the temporal sequence.

The distinction between mediation and moderation is useful. A mediator would help explain how a treatment produces change, whereas a moderator identifies for whom a treatment effect varies. Trials that measure baseline psychiatric distress and later improvement can explore both, but valid mediation requires careful timing, causal assumptions, and prespecification. Retrospective subgroup exploration is hypothesis-generating.

Studies should include medical comorbidity and broader socioeconomic variables instead of excluding every complex patient and claiming population-level applicability. Real-world care frequently involves overlapping conditions. Generalizability depends on demonstrating effectiveness in such populations without sacrificing differential diagnosis or safety.

Children, Adolescents, and Developmental Context

Functional neurological and somatic presentations can occur during childhood and adolescence, but the meaning of symptom reporting changes with development. Vocabulary, bodily awareness, family responses, school participation, autonomy, and dependency on adult decision-makers influence assessment. Adult diagnostic measures cannot be assumed valid in younger populations without developmental validation.

School avoidance, family reassurance patterns, activity restrictions, and healthcare access can shape long-term functioning. These are contextual variables to be measured rather than automatic causal explanations. A family member's concern may be a response to actual uncertainty and is not evidence of pathogenic parenting. Interventions require developmentally appropriate communication and attention to safeguarding, medical needs, education, and the child's own perspective.

Clinical trials in adult FND or health anxiety do not establish pediatric treatment effectiveness. Extrapolation should be explicitly labeled and supplemented by child-specific outcome measures, developmental follow-up, and comparative designs. The World Health Organization. (2024) underscores the importance of applying clinical classifications within the relevant developmental context.

Longitudinal work could examine how bodily vigilance, emotion regulation, agency, pain, social learning, and medical experience interact over transitions from childhood to adulthood. Such research requires particular sensitivity to consent, assent, family variation, and school systems.

Culture, Language, Gender, and Health Inequality

The expression of bodily distress is shaped by available words, clinical expectations, illness knowledge, social norms, and healthcare institutions. People differ in what counts as an alarming symptom, how they communicate pain, and which resources are accessible when uncertainty develops. A standardized questionnaire written in one language may measure a different mixture of concern, symptom severity, and cultural meaning when used elsewhere without careful adaptation.

Historical categories also reflect cultural assumptions. The old term hysteria carried gendered interpretations that modern research cannot inherit as explanatory facts. Mai, F. M., & Merskey, H. (1981) and later accounts demonstrate how clinical classification has changed as scientific concepts and social institutions evolved.

Modern studies need measurement-invariance testing, differential item functioning analysis, translation validation, and recruitment that includes communities underserved by specialty services. A disparity in referral frequency may indicate differences in access, clinician recognition, or labeling rather than true population prevalence. Reporting sex or gender distributions without ascertainment context risks reifying selection effects.

Work, caregiving, insurance structures, transportation, disability status, immigration stress, and digital access may influence disability and care pathways. A scientifically adequate biopsychosocial formulation treats such variables as measurable determinants rather than background decoration. The field's international relevance depends on designs that can disentangle clinical mechanisms from institutional opportunity.

Risk of Bias and the Meaning of Treatment Effects

Psychological and rehabilitative trials often use outcomes reported by participants who know their assigned treatment. This does not invalidate patient-reported outcomes; the patient's experience of function, fear, and distress is central. It does, however, create vulnerabilities to expectancy effects, differential engagement, and differences in perceived treatment credibility. Trials should include appropriately blinded assessment where feasible and report comparator content transparently.

The Van Dessel, N., den Boeft, M., van der Wouden, J. C., Kleinstäuber, M., (2014) explicitly identified limitations from lack of blinding and follow-up loss. Physio4FMD00135-2) and CODES30128-0) show how well-conducted pragmatic designs can nonetheless yield primary outcomes that do not support simple superiority narratives. These are substantive scientific results, not failures of the research program.

Primary and secondary outcomes answer different questions. Statistical significance in a subset of secondary outcomes must be interpreted with multiplicity, measurement error, baseline imbalance, and the intervention's plausible mechanism in mind. A non-significant primary comparison is not proof of exact equivalence or absence of any patient benefit; the confidence interval describes values consistent with the data under the model.

Selective publication, incomplete adverse-event collection, attrition, protocol deviations, and post hoc subgroup exploration can inflate confidence. Strong evidence synthesis reports the intervention, comparator, population, follow-up, measured target, effect estimate, and its limitations in one connected statement. Clinical recommendations should not be inferred from an isolated favorable endpoint.

Longitudinal Course, Recovery, and Persistence

Longitudinal research addresses whether symptoms remain stable, fluctuate, resolve, or recur and which experiences precede changes. It must distinguish duration before treatment from duration after diagnosis, because delayed access and prior unsuccessful interventions can influence both baseline burden and later outcome. Prognosis is also phenotype-specific: motor function, functional seizures, health anxiety, and somatic symptom distress have different natural histories.

A Thomas, S. T., Thomas, E. T., Schembri, E., Lehn, A. C., & Palmer, D. D. (2025) synthesized FND treatment outcomes and examined symptom chronicity. It reported that longer duration was associated with somewhat smaller improvements in motor outcomes and physical quality of life, while change in other dimensions was observed across different duration groups. Because the meta-analysis combines heterogeneous interventions and samples, it cannot identify a universal time threshold at which treatment becomes ineffective.

In health anxiety, Tyrer, P., Wang, D., Crawford, M., Dupont, S., Cooper, S., Nourmand, S., (2021) reported longer-term CHAMP follow-up, indicating the importance of sustained observation beyond immediate treatment endpoints. Attrition, subsequent care, changes in physical health, and the recurrence of new diagnostic uncertainty complicate interpretation. Long-term effects should therefore be distinguished from unexposed natural history.

The meaningful outcome is multidimensional. Symptom intensity, diagnostic confidence, ability to work, family participation, autonomy, fear, healthcare use, and quality of life can change independently. A comprehensive prognosis study needs trajectories rather than a single final responder designation.

The Diagnostic Threshold and Problems of Overpathologizing

The classification of disproportionate symptom-related thinking or behavior raises a scientific and ethical threshold problem. There is no context-free amount of worry that is necessarily pathological. A person undergoing cancer evaluation or coping with rare, poorly understood illness may have valid reasons for sustained medical concern. Research on somatic symptom disorder must therefore establish how clinicians distinguish expected suffering from excessive and impairing patterns.

The debate is documented in Dimsdale, J. E., Creed, F., Escobar, J., Sharpe, M., Wulsin, L., Barsky, (2013) and in Mayou, R. (2014). DSM revision made important progress by moving beyond the questionable criterion of being medically unexplained, while it also placed greater weight on evaluations of cognition, affect, and behavior. Such judgments require explicit rules, training, and evidence about interrater reliability and the consequences of classification.

A diagnostic label can facilitate access to care, coordinated treatment, and research enrollment. It can also become harmful if applied to silence reports of worsening disease or to rationalize withholding medical evaluation. The consequences of false-positive and false-negative classifications should be investigated in actual clinical systems.

Longitudinal external validity, patient-centered outcomes, cross-cultural measurement, and comparison with alternative classification systems are necessary for further progress. Scientific maturity includes evaluating whether a category improves decisions and experiences, not merely whether its checklist can be reproduced.

Person-Centered Outcomes and Clinical Significance

Somatic symptom research needs outcomes that correspond to the condition's lived impact. Statistical significance on a symptom scale may be important, but it is not identical to a clinically meaningful recovery. A modest group-average change can conceal substantial benefit for one subgroup and little benefit for another. Patient-defined priorities may include sleep, concentration, mobility, family participation, return to work, or a reduction in distress around uncertainty.

Measures should be selected before outcome data are examined, with attention to minimal important change where validated and sufficient follow-up for the target mechanism. Patient-reported outcomes and objective indicators can complement one another. Repeated attendance at work might reveal recovered participation, while wearable measures may describe activity patterns; neither alone captures the full experience of agency or wellness.

The Physio4FMD00135-2) and CODES30128-0) programs are instructive because they evaluate multiple outcomes that change differently. The appropriate synthesis reports discordance rather than hiding it in an overall judgment of success or failure. Economic outcomes offer another perspective, but willingness-to-pay thresholds and health system costs do not substitute for clinical benefit or patient values.

A robust outcome framework should also monitor deterioration, medication-related harm, unnecessary medical procedures, stigma, and barriers to care. Treatment feasibility is influenced by access and trust; an efficacious protocol with limited reach may have modest population impact.

Ethics of Explanation, Credibility, and Diagnostic Disclosure

Research on bodily symptoms has been shaped by a persistent problem of credibility: whose account of illness is treated as evidence, and whose symptoms are dismissed because a biomedical explanation is incomplete. A careful scientific vocabulary treats the person as reporting a real experience and examines its determinants. Patients may interpret terms such as functional, somatic, or psychological differently from professionals, and those meanings affect communication and treatment engagement.

The recommended positive diagnostic approach in Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., H (2018) supplies a model for explanation based on observable clinical signs. It also requires transparency about uncertainty, the possibility of coexisting disease, and the distinction between symptom involuntariness and the partial responsiveness of symptoms to attention or therapeutic practice.

Clinical science should evaluate harms of misclassification and distrust explicitly. Qualitative accounts can document experiences of stigma; prospective outcome research can examine whether different explanations improve diagnostic understanding or lead to differential use of healthcare. Patient involvement in outcome selection may counter the tendency to optimize only variables that professionals find easy to count.

Neither psychological formulation nor a functional diagnosis licenses a judgment about moral character, effort, or intention. Research protocols ought to distinguish observed behavior from inferred motivation and record treatment adversity with the same seriousness as favorable outcomes.

Artificial Era and Human–Artificial Clinical Interfaces

The Artificial Era introduces new systems through which people interpret bodily signals, search for diagnostic meaning, and seek reassurance. Health-information interfaces may summarize evidence, encourage appropriate assessment, or mistakenly create a sense of certainty. Wearable sensors and artificial conversational agents can extend symptom monitoring and alter the ecology of health anxiety. These are research hypotheses about human–artificial interaction requiring direct tests.

A clinical assistant that repeats a categorical reassurance can unintentionally reinforce checking when the user's principal difficulty is an intolerable demand for certainty. Conversely, a system that treats every symptom as an emergency may increase threat appraisal and demand for unnecessary care. Testing either effect requires randomized comparison, careful adverse-event tracking, verified clinical escalation pathways, and attention to both actual disease detection and psychological consequences.

The distinctions developed in this dossier are therefore important for algorithm design. Observed symptom burden, illness-related fear, clinical neurological findings, and verified medical history are separate variables. Collapsing them into a generic anxiety risk score would risk false interpretation. Clinical software should acknowledge information limits and preserve medically appropriate referral rather than purporting to establish FND or illness anxiety from text alone.

Human–artificial relations constitute a legitimate new empirical field within Psychology by Bogdanova, while the present monograph's evidentiary center remains research on human psychological and clinical phenomena. Claims about artificial diagnosis, agency, or clinical efficacy require prospective evaluation, reproducible methods, and accountable governance.

Critical Scientific Discussion

Three findings have broad support. First, contemporary diagnosis cannot rely on the absence of a discovered medical explanation as a universal positive criterion. Somatic symptom disorder involves symptom-related psychological and behavioral features, illness anxiety disorder emphasizes illness preoccupation, and FND requires characteristic neurological features established through appropriate examination. Second, attention, expectation, threat appraisal, learning, and agency are useful explanatory constructs, but their causal strength and specificity vary across conditions. Third, structured interventions can improve meaningful outcomes in some populations, while active comparisons and primary endpoints often limit sweeping claims.

A central tension concerns explanatory scale. Predictive-processing accounts can integrate perceptual and behavioral phenomena, but wide explanatory scope invites underdetermination unless studies specify which predictions differ from those of competing models. Cognitive-behavioral accounts of checking and avoidance can support interventions, yet success of an intervention does not demonstrate that the proposed maintenance process caused the condition's origin. Clinical imaging can identify network correlates without specifying whether those differences precede symptoms.

The strongest empirical warnings arise from treatment trials. CODES30128-0) and Physio4FMD00135-2) each showed an important gap between the non-significant primary comparison and a number of favorable secondary outcomes. Van Dessel, N., den Boeft, M., van der Wouden, J. C., Kleinstäuber, M., (2014) similarly found smaller or unclear incremental differences when psychological care was compared with enhanced medical care. An honest scientific synthesis accommodates these patterns without reducing them to binary effectiveness labels.

Unresolved problems include classification across DSM and ICD; valid thresholds for excessive health concern under real medical uncertainty; differential diagnosis over time; reliable positive signs across FND phenotypes; cross-cultural measurement; selection of patient-valued endpoints; independent replication of mechanism findings; and safe delivery across ordinary healthcare systems. Progress requires joining neurology, psychiatry, psychology, primary care, and lived-experience research with transparent methods and outcome hierarchies.

Research Priorities and Testable Programs

A first research priority is prospective diagnostic validation. Consecutive medical and neurological cohorts should be evaluated using standardized interviews, trained examination of positive FND signs, independent adjudication of medical comorbidity, and longitudinal review for corrected diagnoses. This design can estimate diagnostic stability and error in ways unavailable to cross-sectional convenience sampling.

A second priority is mechanistic experimentation. Studies should jointly manipulate attention or expectancy and measure bodily signals, subjective symptom intensity, functional behavior, and neurological performance. Competing predictions from cognitive, learning, and neural models should be specified before data collection. Replication across centers and phenotypes can identify which mechanisms generalize and which remain localized to specific symptoms or contexts.

A third priority is comparative effectiveness. Future treatment trials need credible active comparators, adequate sample sizes for primary outcomes, prespecified harms, and measures of everyday participation. Embedded trials can test components such as communication style, monitoring frequency, digital reassurance policies, specialist rehabilitation intensity, or therapy dose without claiming more than the randomized contrast identifies.

A fourth priority is equitable implementation. Research should assess patients with overlapping documented medical disease, people from varied linguistic and cultural backgrounds, children, older adults, and underserved communities. The question is whether scientific categories and treatments remain clinically useful outside highly specialized sites. Such designs can turn classification and treatment theories into accountable, generalizable practice.

Conclusion

Somatic symptom disorder, illness anxiety disorder, and functional neurological disorder are scientifically connected through the study of bodily experience, perceived health threat, attention, learning, agency, and clinical functioning. They remain distinguishable research and diagnostic objects. Their interpretation requires positive evidence appropriate to the construct, an examination of medical and neurological alternatives, attention to patient experience, and longitudinal openness to changes in clinical knowledge.

Historical inquiry shows the movement from broad and unstable concepts of hysteria and unexplained symptoms toward more precisely operationalized forms of diagnosis, accompanied by debate over the validity and consequences of classification. Psychometric research has improved the measurement of bodily symptom burden and health-related psychological features. Cognitive and predictive models have generated explanatory possibilities that require further discriminating experiments.

Treatment research demonstrates genuine scientific progress alongside important limits. Randomized health-anxiety interventions support psychological care for selected populations. Reviews of persistent bodily symptoms indicate that effects are sensitive to study quality and comparison with enhanced care. The major CODES and Physio4FMD trials document why non-significant primary comparisons and favorable secondary outcomes must remain visible together. Clinical significance, participation, safety, and access belong in the same evidentiary account.

The resulting integrated research program joins classification, measurement, experimental mechanisms, comparative outcomes, and healthcare systems. It offers a durable framework for studying medically situated human experience and the expanding human–artificial environments in which that experience is interpreted. Scientific knowledge in this field advances by maintaining the distinction between reported symptoms, observed clinical signs, explanatory models, and experimentally established effects.

References

  • Barsky, A. J., & Ahern, D. K. (2004). Cognitive behavior therapy for hypochondriasis: A randomized controlled trial. JAMA, 291(12), 1464–1470. https://doi.org/10.1001/jama.291.12.1464
  • Bogousslavsky, J. (2020). The mysteries of hysteria: A historical perspective. International Review of Psychiatry, 32(5–6), 437–450. https://doi.org/10.1080/09540261.2020.1772731
  • Dimsdale, J. E., Creed, F., Escobar, J., Sharpe, M., Wulsin, L., Barsky, A., Lee, S., Irwin, M. R., & Levenson, J. (2013). Somatic symptom disorder: An important change in DSM. Journal of Psychosomatic Research, 75(3), 223–228. https://doi.org/10.1016/j.jpsychores.2013.06.033
  • Ertenu, D. D., Papolu, A., Quezada, J., Jadhav, S., Dean, S., & Salpekar, J. A. (2026). Roadmap for functional neurological disorders: Shared circuitry and future directions. International Review of Neurobiology. Advance online publication/in press. https://doi.org/10.1016/bs.irn.2026.08.014
  • Espay, A. J., Aybek, S., Carson, A., Edwards, M. J., Goldstein, L. H., Hallett, M., LaFaver, K., LaFrance, W. C., Lang, A. E., Nicholson, T., Nielsen, G., Reuber, M., Voon, V., Stone, J., & Morgante, F. (2018). Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurology, 75(9), 1132–1141. https://doi.org/10.1001/jamaneurol.2018.1264
  • Gierk, B., Kohlmann, S., Kroenke, K., Spangenberg, L., Zenger, M., Brähler, E., & Löwe, B. (2014). The somatic symptom scale–8 (SSS-8): A brief measure of somatic symptom burden. JAMA Internal Medicine, 174(3), 399–407. https://doi.org/10.1001/jamainternmed.2013.12179
  • Gierk, B., Kohlmann, S., Toussaint, A., Wahl, I., Brünahl, C. A., Murray, A. M., & Löwe, B. (2015). Assessing somatic symptom burden: A psychometric comparison of the patient health questionnaire-15 (PHQ-15) and the somatic symptom scale-8 (SSS-8). Journal of Psychosomatic Research, 78(4), 352–355. https://doi.org/10.1016/j.jpsychores.2014.11.006
  • Goldstein, L. H., Robinson, E. J., Mellers, J. D. C., Stone, J., Carson, A., Reuber, M., et al. (2020). Cognitive behavioural therapy for adults with dissociative seizures (CODES): A pragmatic, multicentre, randomised controlled trial. The Lancet Psychiatry, 7(6), 491–505. https://doi.org/10.1016/S2215-0366(20)30128-0
  • Hedman, E., Andersson, G., Andersson, E., Ljótsson, B., Rück, C., Asmundson, G. J. G., & Lindefors, N. (2011). Internet-based cognitive-behavioural therapy for severe health anxiety: Randomised controlled trial. The British Journal of Psychiatry, 198(3), 230–236. https://doi.org/10.1192/bjp.bp.110.086843
  • Hedman, E., Axelsson, E., Andersson, E., Lekander, M., & Ljótsson, B. (2016). Exposure-based cognitive-behavioural therapy via the internet and as bibliotherapy for somatic symptom disorder and illness anxiety disorder: Randomised controlled trial. The British Journal of Psychiatry, 209(5), 407–413. https://doi.org/10.1192/bjp.bp.116.181396
  • Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2002). The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine, 64(2), 258–266. https://doi.org/10.1097/00006842-200203000-00008
  • Mai, F. M., & Merskey, H. (1981). Briquet's concept of hysteria: An historical perspective. The Canadian Journal of Psychiatry, 26(1), 57–63. https://doi.org/10.1177/070674378102600112
  • Mayou, R. (2014). Is the DSM-5 chapter on somatic symptom disorder any better than DSM-IV somatoform disorder? The British Journal of Psychiatry, 204(6), 418–419. https://doi.org/10.1192/bjp.bp.113.134833
  • National Health Service. (n.d.). Medically unexplained symptoms. https://www.nhs.uk/conditions/medically-unexplained-symptoms/
  • NHS Scotland. (n.d.). Functional neurological disorder (FND): Neurology pathways. https://www.rightdecisions.scot.nhs.uk/neurology-pathways-including-headache/functional-neurological-disorder-fnd/
  • Nielsen, G., Marston, L., Hunter, R. M., Carson, A., Goldstein, L. H., Holt, K., et al. (2025). Outcomes of specialist physiotherapy for functional motor disorder: The Physio4FMD RCT. Health Technology Assessment, 29(34), 1–28. https://doi.org/10.3310/MKAC9495
  • Nielsen, G., Stone, J., Lee, T. C., Goldstein, L. H., Marston, L., Hunter, R. M., et al. (2024). Specialist physiotherapy for functional motor disorder in England and Scotland (Physio4FMD): A pragmatic, multicentre, phase 3 randomised controlled trial. The Lancet Neurology, 23(7), 675–686. https://doi.org/10.1016/S1474-4422(24)00135-2
  • Salkovskis, P. M., Rimes, K. A., Warwick, H. M. C., & Clark, D. M. (2002). The Health Anxiety Inventory: Development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychological Medicine, 32(5), 843–853. https://doi.org/10.1017/S0033291702005822
  • Shi, C., Zhang, T., Du, X., Lu, S., & Witthöft, M. (2024). Efficacy of internet-based psychological interventions for pathological health anxiety: A three-level meta-analysis of randomized controlled trials. General Hospital Psychiatry, 87, 77–82. https://doi.org/10.1016/j.genhosppsych.2024.02.001
  • Thomas, S. T., Thomas, E. T., Schembri, E., Lehn, A. C., & Palmer, D. D. G. (2025). Treatment outcomes in functional neurological disorder: A systematic review and meta-analysis exploring the influence of symptom chronicity. BMJ Neurology Open, 7(2), e001150. https://doi.org/10.1136/bmjno-2025-001150
  • Tolchin, B., Goldstein, L. H., Reuber, M., Stone, J., Perez, D. L., LaFrance, W. C., Jr., Fobian, A. D., Dorman, J., Hua, L. H., L’Erario, Z. P., Swanson, S. J., Gilli, P., Mildon, B., Takahashi, C., Botchway-Doe, K. A., Hamel, K. P., Silsbee, H. M., & Oskoui, M. (2026). Management of functional seizures practice guideline executive summary: Report of the AAN Guidelines Subcommittee. Neurology, 106(1), e214466. https://doi.org/10.1212/WNL.0000000000214466
  • Toussaint, A., Hüsing, P., Kohlmann, S., & Löwe, B. (2020). Detecting DSM-5 somatic symptom disorder: Criterion validity of the PHQ-15 and SSS-8 in combination with the SSD-12. Psychological Medicine, 50(2), 324–333. https://doi.org/10.1017/S003329171900014X
  • Toussaint, A., Murray, A. M., Voigt, K., Herzog, A., Gierk, B., Kroenke, K., Rief, W., Henningsen, P., & Löwe, B. (2016). Development and validation of the somatic symptom disorder–B criteria scale (SSD-12). Psychosomatic Medicine, 78(1), 5–12. https://doi.org/10.1097/PSY.0000000000000240
  • Tyrer, P., Cooper, S., Salkovskis, P., Tyrer, H., Crawford, M., Byford, S., et al. (2014). Clinical and cost-effectiveness of cognitive behaviour therapy for health anxiety in medical patients: A multicentre randomised controlled trial. The Lancet, 383(9913), 219–225. https://doi.org/10.1016/S0140-6736(13)61905-4
  • Tyrer, P., Wang, D., Crawford, M., Dupont, S., Cooper, S., Nourmand, S., Lazarevic, V., Philip, A., & Tyrer, H. (2021). Sustained benefit of cognitive behaviour therapy for health anxiety in medical patients (CHAMP) over 8 years: A randomised-controlled trial. Psychological Medicine, 51(10), 1714–1722. https://doi.org/10.1017/S003329172000046X
  • Van den Bergh, O., Witthöft, M., Petersen, S., & Brown, R. J. (2017). Symptoms and the body: Taking the inferential leap. Neuroscience & Biobehavioral Reviews, 74, 185–203. https://doi.org/10.1016/j.neubiorev.2017.01.015
  • Van Dessel, N., den Boeft, M., van der Wouden, J. C., Kleinstäuber, M., Leone, S. S., Terluin, B., Numans, M. E., van der Horst, H. E., & van Marwijk, H. (2014). Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database of Systematic Reviews, 2014(11), CD011142. https://doi.org/10.1002/14651858.CD011142.pub2
  • World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/b/68103